NAV-340
/ Sera Medicines, Navigator Medicines, IMBiologics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 04, 2026
IMBiologics and Navigator are also developing NAV-340, a preclinical atopic-focused OX40L bispecific program, with a goal of entering clinical trials next year, Ha said.
(Korea Biomedical Review)
New trial • Immunology
1 to 1
Of
1
Go to page
1